AR and prostate carcinoma: This lead molecule effectively inhibits receptor activity in the low to mid micro-molar concentrations, AR-dependent prostate-specific antigen (PSA) secretion from a variety of prostate cancer cells, and 22Rv1 prostate cancer cell proliferation [2,16].